Detalhe da pesquisa
1.
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
NPJ Breast Cancer;
10(1): 41, 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38844800
2.
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
Oncologist;
2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748596
3.
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Nat Commun;
15(1): 3957, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38730268
4.
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients.
Clin Cancer Res;
2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38709212
5.
Clinicogenomic characterization of inflammatory breast cancer.
bioRxiv;
2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38766070
6.
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
NPJ Breast Cancer;
10(1): 33, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38664404
7.
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer.
NPJ Breast Cancer;
10(1): 26, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575691
8.
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
NPJ Breast Cancer;
10(1): 34, 2024 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38671001
9.
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
NPJ Breast Cancer;
10(1): 28, 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627457
10.
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Nat Commun;
15(1): 2446, 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38503755
11.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Nat Commun;
15(1): 2691, 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538574
12.
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
J Clin Oncol;
42(17): 2050-2060, 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513188
13.
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
J Clin Oncol;
42(15): 1738-1744, 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38422473
14.
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer.
JAMA Oncol;
10(4): 508-515, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38421673
15.
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
Cancer Res Commun;
4(2): 496-504, 2024 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38335301
16.
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
Eur J Cancer;
201: 113920, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38368741
17.
A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
Future Oncol;
20(11): 635-651, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38270051
18.
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.
J Clin Oncol;
: JCO2301071, 2024 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190580
19.
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
Eur J Cancer;
199: 113555, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244363
20.
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.
NPJ Breast Cancer;
10(1): 2, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38167908